Global expansion of the rare disease business under the “Reach Beyond, Together” medium-term management plan

A theme under 4552's 5-year medium-term management plan, “Reach Beyond, Together,” which brings together its R&D and manufacturing capabilities to strengthen its response to rare diseases, while developing an overseas development structure and advancing the global Phase 3 trial of JR-141.